Clinical Trial Update: Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating neoadjuvant and adjuvant tislelizumab for nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN